Peel Hunt Reiterates “Buy” Rating for Circassia Pharmaceuticals (LON:CIR)

Peel Hunt reissued their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a research report report published on Monday morning, ThisIsMoney.Co.Uk reports.

Separately, Numis Securities reissued a buy rating and set a GBX 110 ($1.44) price objective on shares of Circassia Pharmaceuticals in a research note on Wednesday, May 1st.

CIR stock opened at GBX 18.40 ($0.24) on Monday. The stock has a 50-day simple moving average of GBX 18.99 and a two-hundred day simple moving average of GBX 26.81. Circassia Pharmaceuticals has a twelve month low of GBX 13.25 ($0.17) and a twelve month high of GBX 82.70 ($1.08). The firm has a market capitalization of $69.03 million and a PE ratio of -0.54.



About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Read More: Trading Penny Stocks

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.